Company Luckwel Pharmaceuticals Inc.

LWEL

US54959L1017

Managers

Members of the board

Share class

Company contact information

Sector

Sector Shell Companies

Inactive Instrument

Luckwel Pharmaceuticals Inc. creates medicine to cure diseases. The Company is focused on autoimmune disease, human immunodeficiency virus (HIV) / acquired immune deficiency syndrome (AIDS) and infectious diseases. The Companyâs pipelines include LWEL-2120 for the treatment of rheumatoid arthritis (RA), LWEL-2119 for the treatment of HIV and LWEL-2103 for the treatment of COVID-19.

Number of employees: 1

Managers	Title	Age	Since
Kingrich Lee CEO	Chief Executive Officer	49	13-01-01
Mark Carrao DFI	Director of Finance/CFO	-	21-08-31
Michael Silverman CTO	Chief Tech/Sci/R&D Officer	-	-
Priya Jambhekar LAW	General Counsel	-	-

Members of the board	Title	Age	Since
Kingrich Lee CEO	Chief Executive Officer	49	13-01-01

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	147,163,500	14,931,388 ( 10.15 %)	0	10.15 %

Luckwel Pharmaceuticals, Inc.

125 Cambridge Park Drive Suite 301

02140, Cambridge

+617 430 5222

http://www.luckwel.com

address Luckwel Pharmaceuticals Inc.(LWEL)

Financials

Holding Companies

Holding Companies

Investment Holding Companies

Shell Companies

	1st Jan change	Capi.
TRUMP MEDIA & TECHNOLOGY GROUP CORP.	+190.94%	6.96B
CHURCHILL CAPITAL CORP VII	+2.14%	982M
APPLE ISPORTS GROUP, INC.	+41.91%	872M
PERELLA WEINBERG PARTNERS	+26.98%	830M
ARES ACQUISITION CORPORATION II	+1.72%	664M
E7 GROUP	+5.92%	642M
DA ZHONG TRADING GROUP HOLDING COMPANY	-.--%	600M
ADMIRAL ACQUISITION LIMITED	+3.61%	503M
CAPITOL INVESTMENT CORP. VII	-.--%	500M

Shell Companies